Teachers Advisors LLC Buys 4,041 Shares of Insmed, Inc. (INSM)

Teachers Advisors LLC raised its stake in Insmed, Inc. (NASDAQ:INSM) by 1.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 255,863 shares of the biopharmaceutical company’s stock after buying an additional 4,041 shares during the quarter. Teachers Advisors LLC owned approximately 0.33% of Insmed worth $7,978,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. American International Group Inc. lifted its stake in Insmed by 4.6% in the fourth quarter. American International Group Inc. now owns 51,539 shares of the biopharmaceutical company’s stock valued at $1,607,000 after buying an additional 2,255 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Insmed by 137.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,662 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 2,698 shares during the last quarter. Swiss National Bank lifted its stake in Insmed by 2.4% in the fourth quarter. Swiss National Bank now owns 119,600 shares of the biopharmaceutical company’s stock valued at $3,729,000 after buying an additional 2,800 shares during the last quarter. QS Investors LLC lifted its stake in Insmed by 5.2% in the fourth quarter. QS Investors LLC now owns 75,620 shares of the biopharmaceutical company’s stock valued at $2,358,000 after buying an additional 3,771 shares during the last quarter. Finally, California Public Employees Retirement System lifted its stake in Insmed by 4.8% in the fourth quarter. California Public Employees Retirement System now owns 86,600 shares of the biopharmaceutical company’s stock valued at $2,700,000 after buying an additional 4,000 shares during the last quarter. Institutional investors own 99.08% of the company’s stock.

How to Become a New Pot Stock Millionaire

INSM has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $35.00 target price on shares of Insmed in a research note on Thursday, January 4th. Zacks Investment Research upgraded Insmed from a “sell” rating to a “buy” rating and set a $33.00 target price on the stock in a research note on Tuesday, January 9th. BidaskClub upgraded Insmed from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. ValuEngine upgraded Insmed from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Credit Suisse Group initiated coverage on Insmed in a research note on Wednesday, January 17th. They issued a “neutral” rating and a $31.00 target price on the stock. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company’s stock. Insmed has a consensus rating of “Hold” and a consensus target price of $36.90.

Shares of INSM opened at $20.00 on Friday. The firm has a market cap of $1,567.60, a PE ratio of -6.92 and a beta of 1.11. The company has a current ratio of 8.72, a quick ratio of 8.72 and a debt-to-equity ratio of 0.15. Insmed, Inc. has a one year low of $11.49 and a one year high of $33.94.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Friday, February 23rd. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). sell-side analysts anticipate that Insmed, Inc. will post -3.8 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Teachers Advisors LLC Buys 4,041 Shares of Insmed, Inc. (INSM)” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3334500/teachers-advisors-llc-buys-4041-shares-of-insmed-inc-insm.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Check Point Software Technologies  PT Lowered to $117.00
Check Point Software Technologies PT Lowered to $117.00
Village Super Market  & Sprouts Farmers Market  Critical Survey
Village Super Market & Sprouts Farmers Market Critical Survey
Head to Head Review: Randgold Resources  & Agnico Eagle Mines
Head to Head Review: Randgold Resources & Agnico Eagle Mines
Analysts Expect J & J Snack Foods  to Post $1.01 EPS
Analysts Expect J & J Snack Foods to Post $1.01 EPS
Arrow Electronics  and Ituran  Head to Head Analysis
Arrow Electronics and Ituran Head to Head Analysis
Teva Pharmaceutical Industries  Expected to Announce Quarterly Sales of $4.80 Billion
Teva Pharmaceutical Industries Expected to Announce Quarterly Sales of $4.80 Billion


© 2006-2018 Ticker Report. Google+.